SNK-01 is under clinical development by NKGen Biotech and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SNK-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SNK-01 overview

SNK-01 is under development for the treatment of Alzheimer's disease, severe plaque psoriasis, metastatic colorectal cancer, head and neck cancer squamous cell carcinoma, non-small cell lung cancer, leiomyosarcoma, chondrosarcoma,synovial sarcoma, angiosarcoma and sarcoma and other solid tumors and parkinson's disease. The drug candidate comprise of autologous NK cells and administered through intravenous route. It is developed based on superNK technology. It was also under development for the treatment of triple negative breast cancers, Alzheimer's disease and mild cognitive impairment (MCI),

NKGen Biotech overview

NKGen Biotech, a subsidiary of NKMAX Co Ltd, is a biotechnology company specializes in development of autologous, natural killer and allogeneic cell therapies used for the treatment of neurodegenerative and oncology diseases. The company is headquartered in Santa Ana, California, the US.

For a complete picture of SNK-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.